Document:

<PAGE>
                                                                    EXHIBIT 10-B

Class A Common Stock

                  SUBSCRIPTION TO SHARES OF TRUE VALUE COMPANY
WORLD HEADQUARTERS      8600 W. BRYN MAWR AVE.      CHICAGO, ILLINOIS 60631-3505

                        THESE ARE SPECULATIVE SECURITIES

     The undersigned hereby subscribes and agrees to pay for sixty (60) shares
of the Class A Common Stock of TRUE VALUE COMPANY, a Delaware corporation
(herein called the "Company") at the price of $100 per share, such purchase
price to be payable in accordance with the following terms:

                            $6,000.00 check attached
--------------------------------------------------------------------------------

     Said shares shall be issued to the undersigned when fully paid for.

     The undersigned acknowledges receipt of a copy of the currently effective
Prospectus, descriptive of the offering of said shares of Class A Common Stock.
Contemporaneously with the execution hereof, the undersigned is executing and
delivering a Member Agreement with the Company.

     The undersigned in consideration of the acceptance by the Company of this
     subscription and in consideration of the subscriptions of other subscribers
     to shares of the Company upon like terms, agrees with the Company, and
     with the other subscribers and Stockholders of the Company to be bound by
     all of the provisions of the Certificate of incorporation and By-laws of
     the Company, as from time to time amended, including the provisions
     thereof which state the designations and the powers, preferences and
     rights, and the qualifications, limitations and restrictions of the Class
     A Common Stock and Class B Common Stock of the Company, which include,
     without limiting the generality of the foregoing, provisions specifying
     the following rights and powers:

     (I)    the Company's right by a two-thirds vote of its Directors, to
            purchase, when in the best interests of the company, all of the
            Class A and B Common Stock owned by any stockholder;

     (II)   the obligation of the Company to buy and the obligation of any
            stockholder to sell all Class A and Class B Common Stock owned by a
            stockholder in the event of termination of the Member Agreement
            between the Company and the stockholder;

     (III)  the Company's option to purchase, at par value, in the event of any
            proposed or attempted disposition of any common stock of the Company
            by any stockholder; and

     (IV)   the Company's lien upon and right of set-off against all the shares
            of every stockholder to secure payment of such indebtedness of any
            such stockholder to the Company as may from time to time exist for
            whatever reasons.

If the funds necessary to consummate any such purchase of a stockholder's shares
shall have been duly provided by the Company and shall be available to the
stockholder on the date of purchase fixed in the written demand addressed to
the stockholder, then from and after such date all rights and privileges
incident to the ownership of the shares (including, but not limited to, the
right of dividends thereon) shall cease, except only the right to receive the
purchase price plus a sum equal to any dividends declared but unpaid at said
date and accrued Patronage Dividends for the relevant year or a portion thereof
(to be paid in the manner provided for payment Of all Patronage Dividends) all
without interest and subject to the Corporation's liens and right of setoff.
The Terminated Stockholder shall promptly remit any certificates duly endorsed
in blank or with stock powers, and from and after such date of purchase the
Company shall be at liberty to cancel the certificate or certificates
representing said shares upon the books of the Company.

The undersigned understands and agrees that this subscription for shares shall
become effective only upon acceptance thereof by the Company, and further
agrees that all of the terms and provisions of the aforesaid-Prospectus are
incorporated herein by this reference thereto as if set forth herein verbatim.

WITNESS the hand and seal of the undersigned this _________ day of __________,
20__

NAME                                     FIRM NAME
    -------------------------------                ---------------------------
            Signature

Address                                  d/b/a
       ----------------------------           ---------------------------------

City, State, Zip                         Address
                -------------------             --------------------------------

Accepted for TRUE VALUE COMPANY          City, State, Zip
                                                         -----------------------

This        day of          , 20         By
    -------        ----------    --        -------------------------------------
                                                    Signature and Title

By                                                CORPORATIONS AFFIX SEAL
  ---------------------------------
    Signature and Title of Officer

Note:

(1)  If remittance is made by mail, check or money order should be enclosed
     payable to TRUE VALUE COMPANY, 8600 W. Bryn Mawr Ave., Chicago, Illinois
     60631-3505.

     All remittances should be made to this Corporation only through agents duly
     authorized in writing by TRUE VALUE COMPANY to collect subscriptions.

(2)  Signature must correspond to the name in which the certificates are to be
     Issued.exv4w3

 

EXHIBIT 4.3

Statement of Registration Rights

(1) Capitalized terms used in this Statement of Registration Rights shall have the meanings
assigned to them in that certain Asset Purchase Agreement and Plan of Reorganization among Methode
Electronics, Inc. (“Methode”), Cableco Technologies, Inc. (“CTI”), Integrated Technology
Engineering & Manufacturing, Inc. (“ITEM”), Cableco Technologies Corporation (“Cableco”) and the
Selling Stockholders dated as of March 15, 2005.

(2) Methode shall use its best efforts to cause the Restricted Shares (the “Registrable
Securities”) to be registered under the Securities Act of 1933 (“Securities Act”) so as to permit
the resale thereof and in connection therewith shall prepare and file with the Securities and
Exchange Commission (“SEC”) within thirty (30) days following the Closing Date, and shall use its
best efforts to cause to become effective as promptly as practicable and, in any event, no later
than ninety (90) days thereafter, a registration statement (the “Registration Statement”) on Form
S-3 or on such other form as is then available under the Securities Act covering the Registrable
Securities. Each holder of Registrable Securities immediately after the Closing Date (“Holder”)
shall provide all such information and materials to Methode and take all such action as may be
required in order to permit Methode to comply with all applicable requirements of the SEC and to
obtain any desired acceleration of the effective date of such Registration Statement. Such
provision of information and materials is a condition precedent to the obligations of Methode to
cause shares of Registrable Securities to such Holder to be included in the Registration Statement
pursuant to this Statement of Registration Rights. Methode shall not be required to effect more
than one (1) registration under this Statement of Registration Rights. The offering made pursuant
to such registration shall not be underwritten.

(3) Notwithstanding Section (2) of this Statement of Registration Rights, Methode shall be entitled
to postpone the declaration of effectiveness of the Registration Statement for a reasonable period
of time up to sixty (60) days, but in no event shall the postponement of effectiveness extend
beyond 105 days after the Closing Date, if Methode reasonably determines after consultation with
counsel that there exists material nonpublic information about Methode which would be required by
the Securities Act to be disclosed in the Registration Statement, the disclosure of which, in the
good faith determination of Methode board of directors, would be materially detrimental to Methode.

(4) Subject to the limitations of Section (3) of this Statement of Registration Rights, Methode
shall: (i) prepare and file the Registration Statement with the SEC in accordance with Section (2)
with respect to the Registrable Securities and shall use its best efforts to cause the Registration
Statement to become effective as promptly as practicable after filing and to keep the Registration
Statement effective until five (5) years after the Relocation Completion Date; (ii) prepare and
file with the SEC such amendments and supplements to the Registration Statement and the prospectus
used in connection therewith as may be necessary, and to comply with the provisions of the
Securities Act with respect to the sale or other disposition of all securities proposed to be
registered in the Registration Statement until four (4) years after the Relocation Completion Date;
and (iii) furnish to each Holder such number of copies of any prospectus (including any preliminary
prospectus and any amended or supplemented prospectus) in conformity with the requirements of the
Securities Act, and such other documents, as each Holder may reasonably

 

 

request in order to effect the offering and sale of the Registrable Securities to be offered and
sold.

(5) Notwithstanding any other provision of this Statement of Registration Rights, Methode shall
have the right at any time to require that all Holders suspend further open market offers and sales
of Registrable Securities pursuant to the Registration Statement whenever, and for so long as, in
Methode’s reasonable judgment, exercised in good faith after consultation with counsel, there
exists material undisclosed information or events with respect to Methode (the “Suspension Right”).
In the event Methode exercises the Suspension Right, such suspension will continue for the period
of time reasonably necessary for disclosure to occur at a time that is not materially detrimental
to Methode and its stockholders or until such time as the information or event is no longer
material, each as determined by Methode in good faith after consultation with counsel, provided
that Methode will not exercise the Suspension Rights for more than 18 trading days out of any 30
consecutive trading days and for more than an aggregate of 50 trading days over any 12 month
period. Methode agrees to notify the Stockholders’ Representative promptly upon the implementation
and termination of the suspension.

(6) Methode will indemnify each Holder, each of its officers and directors and partners, and each
person controlling such Holder within the meaning of Section 15 of the Securities Act against all
expenses, claims, losses, damages or liabilities (or actions an respect thereof), including any of
the foregoing incurred in settlement of any litigation, commenced or threatened, arising out of or
based on any untrue statement (or alleged untrue statement) of a material fact contained in any
registration statement, prospectus, preliminary prospectus, offering circular or other document, or
any amendment or supplement thereto, incident to any registration, qualification or compliance
effected pursuant to this Statement of Registration Rights, or based on any omission (or alleged
omission) to state therein a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances in which they were made, not misleading, or any
violation or any alleged violation by Methode of any rule or regulation promulgated under the
Securities Act or the Exchange Act in connection with any such registration, qualification or
compliance, and Methode will reimburse each such Holder, each of its officers and directors, and
each person controlling such Holder, each such underwriter and each person who controls any such
underwriter, for any legal and any other expenses reasonably incurred in connection with
investigating, preparing or defending any such claim, loss, damage, liability or action, as such
expenses are incurred, provided that Methode will not be liable to any particular Holder in any
such case to the extent that any such claim, loss, damage, liability or expense arises out of or is
based on any untrue statement or omission or alleged untrue statement or omission, made in reliance
upon and in conformity with written information furnished to Methode by such Holder or controlling
person and specifically for use therein.

(7) It shall be a condition to Methode’s obligations hereunder to register the Registrable
Securities of any Holder that such Holder agrees to indemnify Methode, each of Methode’s directors
and officers, each person who controls Methode within the meaning of Section 15 of the Securities
Act, and each other such Holder, each of its officers and directors and each person controlling
such Holder within the meaning of Section 15 of the Securities Act, against all claims, losses,
damages and liabilities (or actions in respect thereof) arising out of or based on any untrue
statement (or alleged untrue statement) of a material fact contained in any such registration
statement, prospectus, offering circular or other document, or any omission (or

 

 

alleged omission) to state therein a material fact required to be stated therein or necessary to
make the statements therein not misleading, and will reimburse Methode, such other Holders,
directors, officers, persons or control persons for any legal or any other expenses reasonably
incurred in connection with investigating or defending any such claim, loss, damage, liability or
action, as such expenses are incurred, in each case to the extent, but only to the extent, that
such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in
such registration statement, prospectus, offering circular or other document in reliance upon and
in conformity with written information furnished to Methode by such Holder specifically for use
therein.

(8) Each party entitled to indemnification under Section (6) or (7) of this Statement of
Registration Rights (the “Indemnified Party”) shall give notice to the party required to provide
indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual
knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party
to assume the defense of any such claim or any litigation resulting therefrom, provided that
counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation,
shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld), and
the Indemnified Party may participate in such defense at such party’s expense; provided, however,
that an Indemnified Party (together with all other Indemnified Parties which may be represented
without conflict by one counsel) shall have the right to retain one separate counsel, with the fees
and expenses to be paid by the Indemnifying Party, if representation of such Indemnified Party by
the counsel retained by the Indemnifying Party would be inappropriate due to differing or
potentially differing interests between such Indemnified Party and any other party represented by
such counsel in such proceeding. The failure of any Indemnified Party to give notice as provided
herein shall not relieve the Indemnifying Party of its obligations under Section (6) or (7) of this
Statement of Registration Rights unless the failure to give such notice is materially prejudicial
to an Indemnifying Party’s ability to defend such action. No Indemnifying Party, in the defense of
any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to
entry of any judgment or enter into any settlement which does not include as an unconditional term
thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all
liability in respect to such claim or litigation.

(9) Promptly after the Closing, Methode and its counsel will instruct in writing Methode’s transfer
agent to permit the sale or transfer of the Registrable Securities by any Holders notwithstanding
the legend required hereunder (and without the legend) to the extent that: (i) the shares proposed
to be sold or transferred: (A) are not restricted hereunder and (B) are being sold or transferred
by the Holder pursuant to and in accordance with the Registration Statement, and (ii) the
Suspension Right is not then in effect. Methode agrees to promptly notify its transfer agent of
the implementation and termination of any Suspension Right then in effect. If a request for sale
or transfer or release of legends is made by or on behalf of a Holder or by Methode’s transfer
agent, Methode or its counsel shall respond promptly to such request, and in any event within two
(2) business days of receipt of the request by Methode’s counsel, and will approve the sale,
transfer or release of the legends, as appropriate, if the above conditions are satisfied.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]